These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38864578)

  • 1. Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV.
    Hwang YJ; Lesko CR; Brown TT; Alexander GC; Zalla LC; Keruly JC; Snow LN; Pytell JD; Falade-Nwulia O; Jones JL; Moore RD; Fojo AT
    AIDS; 2024 Sep; 38(11):1696-1702. PubMed ID: 38864578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
    Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
    Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens.
    Milic J; Renzetti S; Ferrari D; Barbieri S; Menozzi M; Carli F; Dolci G; Ciusa G; Mussini C; Calza S; Guaraldi G
    AIDS; 2022 Oct; 36(12):1643-1653. PubMed ID: 35727163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
    Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
    Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.
    Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P;
    PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
    Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
    Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents.
    The RESPOND Study Group
    AIDS; 2021 May; 35(6):869-882. PubMed ID: 33443370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
    Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
    HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
    Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
    Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus.
    Chow W; Donga P; Côté-Sergent A; Rossi C; Lefebvre P; Lafeuille MH; Emond B; Hardy H
    Curr Med Res Opin; 2020 Aug; 36(8):1313-1323. PubMed ID: 32459155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
    O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
    J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
    Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
    BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus.
    O'Halloran JA; Sahrmann J; Parra-Rodriguez L; Vo DT; Butler AM; Olsen MA; Powderly WG
    Clin Infect Dis; 2022 Dec; 75(12):2060-2065. PubMed ID: 35521785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus.
    Asundi A; Olson A; Jiang W; Varshney SP; White LF; Sagar M; Lin NH
    AIDS Res Hum Retroviruses; 2022 Mar; 38(3):208-215. PubMed ID: 34877881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
    Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
    Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.